Ceva-Phylaxia Zrt.

What Ceva-Phylaxia Zrt. does

Ceva-Phylaxia Zrt. is a Budapest-headquartered veterinary pharmaceutical manufacturer and one of the largest biologicals production sites in the Central and Eastern European region. It operates as a subsidiary of the French animal-health group Ceva Santé Animale, acting as a core R&D and manufacturing hub for vaccines and pharmaceuticals targeting companion animals (notably pheromone-based products such as FELIWAY and ADAPTIL), ruminants, swine, and poultry. The site operates multiple production facilities in Budapest and a newly commissioned vaccine plant at Monor, holds what the company describes as the EU's largest cryogenic storage facility for biological materials, and has cumulatively produced in excess of 50 billion vaccine doses. Its R&D activity is protected by proprietary patents including Phytosphingosine, Imuvant and Delicament, supported by more than 42 published clinical studies on its pheromone franchise, and the company holds the Hungarian national HPAI vaccine bank mandate through Nébih.

The firm's revenue model combines B2B sales of licensed veterinary vaccines and pharmaceuticals, sold primarily via the global Ceva distribution network spanning 110+ countries, with a growing contract and government services line via the HPAI vaccine-bank mandate. Channel structure is indirect: products reach veterinarians, livestock producers and smallholder poultry operations through wholesalers, veterinarian prescription channels, and direct institutional/government relationships for the stockpile business. Pricing is consumption-based per dose (with biological-manufacturing premium over generic chemical pharma), and customer relationships are framed around disease-prevention protocols rather than transactional SKU purchases, which creates recurring, regimen-driven demand for the companion-animal pheromone and livestock vaccine franchises. R&D is differentiated by strain-bank depth, fermentation and cryo-storage scale, and emerging capabilities in novel DNA-vaccine platforms through partnerships such as the Touchlight dbDNA collaboration.

Go-to-market rests on Ceva-group veterinary field forces and partner distributors across regions; the Budapest site itself has grown to 1,300+ employees and has been linked to group-level capital actions including the 2025 minority investment by Institut Mérieux and ARCHIMED and the 2024 acquisition of Scout Bio. Revenue mechanics are dominated by volume of biological doses shipped rather than software-style recurring fees, and the HPAI bank mandate adds a stable, government-anchored revenue line independent of commercial livestock cycles.

Name

Ceva-Phylaxia Zrt.

Legal name

Ceva-Phylaxia Oltóanyagtermelő Zrt.

Website

https://ceva.hu

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

Ceva-Phylaxia Zrt. is a Budapest-headquartered veterinary pharmaceuticals and vaccines manufacturer, operating as the biologicals R&D and production hub for Ceva Santé Animale, serving companion-animal, ruminant, swine, and poultry markets across 110+ countries.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

Keywords

• Veterinary vaccines
• Animal pharmaceuticals
• Poultry vaccines
• Swine vaccines
• Companion animal health

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Vaccine sales: Production and sale of veterinary vaccines for poultry, swine, cattle, sheep, goats, and companion animals. Revenue from both domestic Hungarian market and export to global markets through Ceva group distribution network.
2. Pharmaceutical products: Sale of veterinary pharmaceuticals including antibiotics, anti-inflammatories, cardiovascular drugs, dermatology products, and parasiticides for all animal segments.
3. Digital services and applications: Value-added services including the Ceva Lung Program mobile application for swine health management, which supports product adoption and customer loyalty.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ceva-Phylaxia Zrt. researches, develops, manufactures, and markets veterinary vaccines and pharmaceutical products for companion animals (dogs, cats), ruminants (cattle, sheep, goats), swine, and poultry. The portfolio spans prescription pharmaceuticals (anti-infectives, parasiticides, cardiology, dermatology, reproductive management), biological vaccines for livestock and poultry, pheromone-based behavioral therapies, and digital herd-health tools (Ceva Lung Program app). Products are sold through veterinary professionals and B2B livestock channels, with global reach delivered via the Ceva Santé Animale group's distribution network.

Product overview

Ceva-Phylaxia Zrt. is a veterinary pharmaceutical company and a subsidiary of Ceva Santé Animale, specializing in research, development, production, and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine, and poultry. The product portfolio includes vaccines (COGLAPIX, HYOGEN, COXEVAC, VECTORMUNE ND), anti-infectives (VETRIMOXIN LA, TIAMVET), parasiticides (VECTRA, FIPROLEX), reproductive management products (SYNCRO-PART, MELOVINE/REGULIN), dermatology products (DOUXO), behavioral products (FELIWAY, ADAPTIL), cardiology products (CARDALIS), and digital tools (Ceva Lung Program App). The company operates primarily from Hungary with global distribution through the Ceva group network.

Differentiator

Problem solved

Functional benefit

Brands

• Ceva Lung Program: iPad/Android mobile application for recording lung scores, processing results, and managing pig herd health data
• Ceva Lung Program App
• Vectra
• Vectormune
• Transmune
• FELIWAY
• ADAPTIL
• DOUXO

Products and services

• FELIWAY Feline facial pheromone analogue spray and diffuser for managing stress-related behaviors in cats such as urine-marking, scratching, and aggression; sold through veterinary channels to pet owners.
• ADAPTIL Dog Appeasing Pheromone (D.A.P.) product available as spray, diffuser, or collar for managing stressful situations in dogs including separation anxiety, weaning, transport, and noise fear.
• DOUXO Topical dermatology product line containing the Ceva-patented Phytosphingosine molecule for restoring skin barrier function in dogs and cats, available as shampoos, foam, and sprays.
• CARDALIS Combination of benazepril and spironolactone for treating congestive heart failure in dogs by blocking the Renin Angiotensin Aldosterone System.
• VECTRA Ectoparasiticide product line for dogs and cats providing broad-spectrum protection against vectors including fleas, ticks, and mosquitoes.
• HYOGEN Vaccine against Mycoplasma hyopneumoniae with Imuvant adjuvant for enzootic pneumonia protection in swine.
• COGLAPIX Vaccine based on bacterial toxoids for Actinobacillus pleuropneumoniae providing protection against all serotypes of swine pleuropneumoniae.
• COXEVAC Vaccine for Coxiella burnetii (Q fever) in cattle, sheep, and goats, reducing bacterial excretion in vaccinated animals.
• VECTORMUNE ND Recombinant HVT vector vaccine expressing Newcastle disease virus D-26 strain fusion protein for poultry.
• SYNCRO-PART Intravaginal sponges containing fluorogestone for synchronization of estrus in sheep and goats, combined with PMSG for breeding management.
• MELOVINE/REGULIN Melatonin implant for sheep and goats that induces estrus and ovarian activity by simulating shortened day length.
• VETRIMOXIN LA Long-acting amoxicillin injectable suspension for treating respiratory affections and neonatal diseases in swine.
• TIAMVET Tiamulin-based oral powder or premix for treating swine dysentery and enzootic pneumonia in pigs.
• GLEPTOSIL Gleptoferron injectable for treatment and prevention of iron-deficiency anemia in piglets.
• Ceva Lung Program App iPad/Android mobile application for recording lung scores, processing and summarizing slaughterhouse results, and managing data for swine herd health monitoring.

Quantifiable outcome

• 50 billionth domestic poultry vaccine produced in Hungary
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered strategic, core and minor.

• TouchlightstrategicTechnology or Integration · 22 January 2025Ceva Animal Health and Touchlight signed an agreement to use Touchlight's dbDNA technology in animal health applications. This partnership enables Ceva to leverage innovative DNA technology for vaccine and therapeutic development.
• Budapest University of Technology and Economics (BME)coreStrategic or Co-development Partner · 18 June 2024Strategic cooperation to develop practical training for students in technical fields at Ceva-Phylaxia. The partnership enhances technical education while building future talent pipeline.
• Törekvés S.E.minorGTM or Marketing Partner · 7 March 2024Ceva-Phylaxia became a supporting partner of Törekvés S.E. Fencing and Wheelchair Fencing Sports Club as part of community engagement and CSR activities.
• Nébih (National Food Chain Safety Office)coreStrategic or Co-development Partner · 27 February 2024Collaboration to establish HPAI (Highly Pathogenic Avian Influenza) vaccine bank. Nébih and Ceva-Phylaxia created emergency vaccine reserves for avian influenza outbreak response.
• Scout BiostrategicTechnology or Integration · 1 January 2024Ceva Santé Animale acquired Scout Bio, opening the path for pioneering innovations in companion animal therapy through gene therapy and advanced biologics.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Phibro Animal Health: Phibro Animal Health is a US-listed animal health and nutrition company focused on livestock (cattle, poultry, swine) vaccines, antibiotics, and nutritional specialties. Highly comparable to Ceva-Phylaxia's livestock vaccine and pharmaceutical production focus.
• Vetoquinol: Vetoquinol is an independent veterinary pharmaceutical group headquartered in France focused on livestock and companion animal health products. It competes with Ceva-Phylaxia in cattle, swine, and pet pharmaceuticals with comparable mid-tier scale.
• Hipra: Hipra is a Spain-headquartered independent veterinary pharmaceutical company specializing in biologicals and vaccines for livestock and companion animals. Directly comparable to Ceva-Phylaxia in vaccine R&D and manufacturing scale, with a similar species mix across poultry, swine, and cattle.
• Virbac: Virbac is a France-based independent veterinary pharmaceutical company specializing in vaccines, parasiticides, and specialty therapeutics for companion and food animals. It is closely comparable to Ceva-Phylaxia in mid-sized animal health positioning with similar species and product mix.
• Dechra Pharmaceuticals: Dechra is a UK-based veterinary pharmaceuticals specialist with a strong focus on companion animal specialty therapeutics (endocrinology, dermatology, cardiology, analgesia). Comparable to Ceva-Phylaxia's companion animal pharmaceutical sub-portfolio including DOUXO dermatology and Cardalis cardiology.

Regional players

• Indian Immunologicals: Indian Immunologicals is a major veterinary vaccine manufacturer in India producing livestock and companion animal vaccines at scale. Comparable to Ceva-Phylaxia in vaccine development and production capabilities, though primarily serving the South Asian market.

Broad incumbents

• Merck Animal Health (MSD Animal Health): MSD Animal Health is a leading global animal health business with deep vaccine franchises across poultry, swine, and companion animals. Comparable to Ceva-Phylaxia in production scale, regulatory footprint, and broad species coverage, particularly in biologicals.
• Elanco Animal Health: Elanco is a top-5 global animal health company offering vaccines, parasiticides, and therapeutics across companion and production animals. It is a direct competitor to Ceva-Phylaxia's portfolio across livestock and pet segments.
• Boehringer Ingelheim Animal Health: Boehringer Ingelheim's animal health division is a top-3 global player offering vaccines and pharmaceuticals across all major species. It directly competes with Ceva-Phylaxia in swine and cattle vaccines (formerly overlapping with Ceva via the 2017 Merial asset swap) and has similar reach across companion animals.
• Zoetis: Zoetis is the world's largest standalone animal health company with a comprehensive portfolio of vaccines, parasiticides, and pharmaceuticals across companion and livestock species. It competes head-to-head with Ceva-Phylaxia in vaccines for poultry, swine, and cattle and sets the benchmark for industry R&D spending.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ceva-phylaxia-zrt.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceva-Phylaxia Zrt.